Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

Pfizer Inc. (NYSE: PFE) continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology ...

From September 2026, all newly qualified pharmacists will be independent prescribers on the day of their registration. This presents an opportunity for NHS England to commission clinical services from ...

Scientists have calculated the value of pi to one hundred trillion digits, but you don't have to be a mathematician to understand it. Pi shows up everywhere, from particle physics to sacred geometry.

Merck’s Keytruda Combo for Urothelial Carcinoma Gets EU Approval: The European Commission granted approval to Merck’s Keytruda in combination with Astellas/Pfizer’s antibody-drug conjugate ...

The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Please see Prescribing Information for KEYTRUDA (pembrolizumab ...

Overall survival (OS) data for KEYTRUDA ® (pembrolizumab) in earlier stages of women’s cancers, including high-risk early-stage triple-negative breast cancer (KEYNOTE-522) and high-risk locally ...